N/A N=9 rTMS and Botulinum Toxin in Primary Cervical Dystonia
Primary Cervical Dystonia · Dystonia
Primary: Dystonia Severity as Assessed by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 13; 17 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5 Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults
Dystonia
Primary: Change From Baseline in Burke-Fahn-Marsden Dystonia Rating Scale — 14.7 change in points on a scale
N/A N=9 Deep Brain Stimulation in Patients With Dystonia
Dystonia
Primary: The Toronto Western Spasmodic Rating Scale (TWSTRS) Movement Scores Measured Before DBS Surgery (Baseline) and at 12 Months — 33.5 TWSTRS total score change
Phase 2 N=16 Amlodipine Plus Botulinum Toxin for Focal Dystonia
Focal Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTR) Sum Score — -6.00; -3.23 units on a scale
N/A N=8 Identification of Optimal Stimulation Site for Cervical Dystonia Symptoms: An Exploratory Study
Cervical Dystonia · Spasmodic Torticollis
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — -3.0; 0.25; -2.9; -1.5 units on a scale
N/A N=38 Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
Dystonia-Parkinsonism, Adult-Onset · Parkinson Disease
Primary: Burke-Fahn-Marsden Dystonia Rating Scale — 3.5 units on a scale — p=<0.001
N/A N=5 Dystonia Treatment With Injections Supplemented By Transcranial Magnetic Stimulation
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 17; 16.6; 17; 15.8 score on a scale — p=0.691
N/A N=12 Neuromodulation Therapy for Task-Specific Dystonia
Isolated Focal Hand Dystonia
Primary: Feasibility of Accurately Delivering TMS During the Task of Writing as Measured by Number of Participants Who Completed the TMS Sessions — 12; 12; 11 Participants
N/A N=6 Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial
Spasmodic Dysphonia · Laryngeal Dystonia · Deep Brain Stimulation
Primary: Unified Spasmodic Dysphonia Rating Scale (USDRS) — 2.5; 3.75 units on a scale — p=0.025
N/A N=12 Repetitive Transcranial Magnetic Stimulation (rTMS) for Dystonia and Tremor
Dystonia · Tremor
Primary: Cognitive Assessment Using MoCA Version 7.1 Scores — 25.45; 27 units on a scale
N/A N=20 rTMS in Spasmodic Dysphonia
Spasmodic Dysphonia · Laryngeal Dystonia
Primary: Adverse Response to rTMS — 0; 0 Participants
Phase 3 N=516 Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
Cervical Dystonia
Primary: Change From Baseline in the Total Score of the Tsui Rating Scale (Patient in Sitting Position) at the First On-treatment Visit (Week 4 or Week 12) — -3.8; -4.0; -3.8…
Phase 2 N=9 rTMS and Retraining in Focal Hand Dystonia
Focal Dystonia
Primary: Change From Baseline in Global Rating of Change at Posttest (Day 5) — 1.3; 1.2 units on a scale
Phase 3 N=63 A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
Cerebral Palsy, Dyskinetic
Primary: Change From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part II Total Score (Movement Disorder Severity, Centrally Read) at Week 15 — -0.4; -1.5…
Phase 2 N=15 An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia
Dystonia, Primary
Primary: Proportion of Study Subjects Able to Titrate up to the Maximum Tolerated Dose — 6 Participants
Phase 2 N=242 Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia
Cervical Dystonia
Primary: Change From Baseline in Observed Total Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Score at Week 4 of Treatment Cycle 1 — 40.4; 41.5; 39.6; -10.3 Scores…
N/A N=10 rTMS Therapy for Primary Orthostatic Tremor
Primary Orthostatic Tremor
Primary: Change in Fullerton Advanced Balance (FAB) Scale Total Score After rTMS — 2.8; 0.9 change in score on a scale
Phase 2 N=133 Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis
Cervical Dystonia · Spasmodic Torticollis
Primary: Mean Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Treatment — 3; 8.9; 7.6; 10.5 Points on a Scale
N/A N=1,046 CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score — 27.1 score on a scale
Phase 4 N=16 Neurotoxin and Physical Therapy
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 28; 20.1 total score on a scale
Phase 1 N=17 Repetitive Transcranial Magnetic Stimulation for the Treatment of Focal Hand Dystonia
Dystonia, Focal, Task-specific
Primary: Cortical Silent Period — 9; 1.61 milliseconds
Phase 4 N=10 Botox for Cervical Dystonia Following EMG Mapping
Cervical Dystonia
Primary: Pre- and Post-injection Toronto Western Spasmodic Torticollis Rating Scale(TWSTRS): Global Clinical Impression Scale (GCI); Visual Analog Scale(VAS)
Phase 2 N=21 Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand
Dystonia
Primary: Physician Global Perception of Change - Blinded Rater 1 — 1; 1; 1; 4 Participants
N/A N=12 rTMS and Botulinum Toxin in Benign Essential Blepharospasm
Benign Essential Blepharospasm
Primary: Change in JRS Severity Score — -1.8; -0.1 Change in score
Phase 2 N=13 Pilot Trial of Botulinum Toxin and Occupational Therapy for Writer's Cramp
Dystonia
Primary: Using a Patient Rated Subjective Scale (Visual Analogue Scale), Change From Baseline With Botulinum Toxin Therapy Plus Occupational Therapy Compared to Botulinum Toxin…
Phase 2 N=7 Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia
Oromandibular Dystonia · Cranial Dystonia
Primary: Percent Change of the Sum of the Eyes, Mouth, Speech and Swallowing Subscores of the Burke-Fahn-Marsden (BFM) Dystonia Scale. — 12.16; 31.25 percent change
Phase 4 N=502 Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
Cervical Dystonia
Primary: Treatment Assessment Scale (TAS), 4 Wks Post-injection Compared to Baseline (Time 0), Rating of Cervical Dystonia Symptoms — 0.9 points on a scale
Phase 2 N=61 A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia
Cervical Dystonia
Primary: Number of Participants With Treatment-Related Serious Adverse Events — 0; 0; 0; 0 Participants
Phase 2 N=53 Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response
Spasmodic Dysphonia · Voice Tremor
Primary: Number of Participants Who Reported Positive Effects. — 17; 20 Participants
Phase 3 N=298 Addressing Involuntary Movements in Tardive Dyskinesia
Tardive Dyskinesia
Primary: Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM) — -1.4; -2.1; -3.2; -3.3…